Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025) [0.03%]
2025年亚洲胃肠间质瘤诊断与管理共识意见更新
Hidekazu Hirano,Yoichi Naito,Tsuyoshi Takahashi et al.
Hidekazu Hirano et al.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor arising from the gastrointestinal tract. Accurate pathological diagnosis and appropriate treatment for this malignancy require a multidisciplinary approach. In consi...
Germline whole-exome sequencing identifies CTNND1 as a candidate gene for hereditary gastric cancer in a large Brazilian cohort [0.03%]
运用外显子组测序技术鉴定CTNND1为胃癌易感基因
Deivid Calebe de Souza,Thaliane Buranello,Dario Tenorio Tavares Neto et al.
Deivid Calebe de Souza et al.
Background: Gastric cancer is the fifth most commonly diagnosed cancer. Although 10% of cases show familial clustering, a monogenic hereditary cause is rarely observed. Little is known about the molecular profile of famil...
A systematic review of factors associated with the patient and diagnostic intervals in gastric cancer [0.03%]
胃癌患者和诊断间隔相关因素的系统综述
John A Queenan,Noor Breik,Shaila J Merchant et al.
John A Queenan et al.
Introduction: Many patients with gastric cancer in low-incidence countries are diagnosed at advanced stages, underscoring the need for earlier detection to enable curative treatment. This systematic review aimed to summar...
Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer [0.03%]
正常肌肉量胃癌患者中预后不良高危患者的多中心回顾性验证研究
Ryota Matsui,Kazuyoshi Yamamoto,Yoshiro Yukawa et al.
Ryota Matsui et al.
Background: Although a low skeletal muscle mass index (SMI) leads to poor overall survival (OS) after gastrectomy in patients with gastric cancer, the cutoff value that predicts long-term survival in patients with normal ...
Clinicopathological characteristics of gastric papillary adenocarcinoma compared with tubular adenocarcinoma [0.03%]
乳头状腺癌的临床病理特征与管状腺癌的比较研究
Taku Hattori,Masanori Terashima,Atsushi Ochiai et al.
Taku Hattori et al.
Background: Papillary adenocarcinoma (Pap) is a relatively rare histological subtype of differentiated adenocarcinoma, and its biological behavior has not been fully elucidated. The present study aimed to clarify the clin...
Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study [0.03%]
纠正：G-KNIGHT研究——nivolumab联合化疗一线治疗日式真实世界环境下晚期或复发胃癌的有效性和安全性观察性研究
Shigenori Kadowaki,Tomoyuki Otsuka,Keiko Minashi et al.
Shigenori Kadowaki et al.
Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review [0.03%]
从实验室到临床：晚期胃癌腹腔转移的Taxane颗粒剂缓释减积手术灌注治疗技术进展及疗效评估叙事综述
Joji Kitayama
Joji Kitayama
Peritoneal metastasis (PM) is the most common and clinically devastating mode of spread in Gastric Cancer. Despite advances in systemic therapy, outcomes for gastric cancer with peritoneal metastasis (GCPM) remain poor, largely because the ...
CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer [0.03%]
CXCL12上调PD-L1表达并促进胃癌相关巨噬细胞M2极化以赋予抗PD-1耐药性
Chao Wu,Boya Li,Huiling Li et al.
Chao Wu et al.
Objective: Immunotherapy offers promise for gastric cancer (GC) patients, yet its efficacy is substantially limited by high rates of treatment resistance, the mechanisms of which remain incompletely characterised. We aime...
Comment on 'Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer' [0.03%]
关于《肿瘤内HER2异质性对HER2阳性胃癌患者接受曲妥珠单抗德鲁替康疗效的影响》的述评
Xuezhe Yuan,Kaibo Guo,Song Zheng
Xuezhe Yuan
Long-term acid suppression after gastric cancer treatment: clarifying denominators and time-dependent exposure [0.03%]
胃癌治疗后的长期抑酸：明确受试者基数和时间依赖性暴露关系
Xiaohe Zhang,Chaochi Yue
Xiaohe Zhang